|
Market Closed -
NYSE
16:00:02 2026-09-21 EDT
|
After hours 20:00:00 | |||
| 87.60 USD | -1.40% |
|
88.50 | +1.03% |
| 09-17 | CVS Health Expands Cancer Prior Authorization Bundles | MT |
| 09-17 | CVS Health's Aetna to streamline cancer treatment approvals | RE |
| Market Cap | 112B 97.69B 92B 83.79B 157B 10,734B 157B 1,102B 425B 5,468B 421B 412B 17,644B | P/E 2026 * |
12.7x | P/E 2027 * | 12.1x |
|---|---|---|---|---|---|
| Enterprise Value | 164B 143B 135B 123B 230B 15,706B 230B 1,612B 621B 8,001B 616B 602B 25,818B | EV / Sales 2026 * |
0.39x | EV / Sales 2027 * | 0.37x |
| Free-Float |
71.17% | Yield 2026 * |
3.04% | Yield 2027 * | 3.13% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CVS | Delayed | |
CBOE
| CVS | Real-time | |
|
Tradegate
| CVS | Real-time | |
|
Deutsche Boerse AG
| CVS | Delayed | |
|
Boerse Muenchen
| CVS | Real-time | |
|
Mexican S.E.
| CVS * | End-of-day quote | |
|
London S.E.
| 0HRS | Delayed | |
|
Xetra
| CVS | Delayed | |
|
Santiago S.E.
| CVSCL | End-of-day quote | |
|
Swiss Exchange
| CVS | Delayed | |
|
CBOE
| Real-time | ||
|
CBOE
| 0HRS | Real-time | |
|
Santiago S.E.
| CVS | End-of-day quote | |
|
Borsa Italiana
| 1CVS | End-of-day quote | |
|
Lima
| CVSUS | End-of-day quote | |
|
Wiener Boerse
| CVS | End-of-day quote | |
|
Börse Stuttgart
| CVS | Delayed | |
|
Swiss Exchange
| CVS | Delayed |
Last Transcript: CVS Health Corporation
| 1 day | +1.03% | ||
| 1 week | -8.32% | ||
| Current month | -6.72% | ||
| 1 month | -5.83% | ||
| 3 months | -10.90% | ||
| 6 months | +22.55% | ||
| Current year | +10.38% |
| 1 week | 87.19 |  | 94.95 |
| 1 month | 87.19 | | 98.5 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 2024-10-16 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 2025-05-11 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 2007-02-28 |
Anne Finucane
BRD | Director/Board Member | 73 | 2011-01-19 |
| Director/Board Member | 71 | 2015-03-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/31/26 | Tax | Chief Financial Officer | -2,478 | 0.0002% | ||
| 5/31/26 | Tax | Chief Technology Officer | -7,618 | 0.0006% | ||
| 5/21/26 | Glenview Capital Management LLC
| Sell | Company | -748,462 | 0.0584% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.40% | -8.32% | +16.92% | +21.85% | 112B | |
| -0.41% | +0.11% | +5.88% | +68.08% | 92.22B | |
| -0.42% | +0.47% | -2.05% | +47.89% | 29.13B | |
| -0.64% | +2.94% | +33.38% | +98.25% | 27.03B | |
| -1.00% | -1.56% | -9.28% | -2.94% | 21.22B | |
| -0.39% | -1.34% | +37.25% | +287.60% | 21.01B | |
| +2.39% | +2.89% | -9.69% | +43.85% | 16.26B | |
| +0.41% | -1.79% | -10.19% | -8.82% | 11.81B | |
| -0.83% | -3.69% | +40.09% | +78.14% | 11.63B | |
| -0.68% | +2.98% | -9.63% | +94.69% | 10.81B | |
| Average | -0.05% | -1.10% | +9.27% | +72.86% | 35.32B | |
| Weighted average by Cap. | +0.13% | -2.61% | +11.19% | +60.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 418B 364B 343B 312B 586B 40,024B 587B 4,109B 1,584B 20,388B 1,569B 1,535B 65,791B | 430B 375B 353B 321B 603B 41,178B 603B 4,227B 1,629B 20,976B 1,615B 1,579B 67,689B |
| Net income | 8.88B 7.75B 7.3B 6.64B 12.46B 851B 12.47B 87.38B 33.68B 434B 33.37B 32.63B 1,399B | 9.34B 8.14B 7.67B 6.98B 13.1B 895B 13.11B 91.85B 35.4B 456B 35.08B 34.31B 1,471B |
| Net Debt | 51.91B 45.26B 42.63B 38.82B 72.78B 4,973B 72.87B 510B 197B 2,533B 195B 191B 8,174B | 48.85B 42.6B 40.12B 36.54B 68.5B 4,680B 68.59B 480B 185B 2,384B 184B 179B 7,694B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-21 | US$87.60 | -1.40% | 10,137,932 |
| 26-09-18 | US$88.84 | -1.58% | 21,880,291 |
| 26-09-17 | US$90.27 | -1.58% | 7,434,654 |
| 26-09-16 | US$91.72 | -2.93% | 7,235,058 |
| 26-09-15 | US$94.49 | -1.11% | 5,002,424 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
